| News
Polyphor receives up to 18 million dollars for development of antibiotics
15.10.2020
The Allschwil-based company Polyphor has received a second funding award from the global consortium CARB-X to combat antimicrobial resistance. Polyphor will be provided with initial funding of up to 2.62 million US dollars for its innovative antibiotics program. A maximum of 15.82 million dollars has been earmarked for later milestones.

As the life sciences company Polyphor wrote in a press release, this funding is the second major support by the global public-private consortium CARB-X and follows a previous grant in 2019. This partnership led by Boston University is dedicated to supporting the development of antibacterial products, to diagnose, prevent and treat drug-resistant infections. Polyphor is located in Allschwil in the canton of Basel-Landschaft. The Basel area is known as a leading center for antibiotic research.
This award will support the development of the novel class of antibiotics discovered by Polyphor and the University of Zurich. These show potent and specific antimicrobial activity against Enterobacteriaceae, including extremely drug resistant strains. They are among the priority-1 pathogens, as classified by the World Health Organization.
CARB-X will provide Polyphor with initial funding of up to 2.62 million US Dollars to complete the hit-to-lead stage. Up to 15.82 million dollars will additionally be granted if certain project milestones are met.
“CARB-X fosters the best science and most promising early development R&D-projects in the world,” explains Polyphor CEO Gökhan Batur in the press release. “This second award is a strong validation of our innovative antibiotic platform and an important milestone in the implementation of our renewed strategy in this field presented earlier this year.”
“Serious infections are a global health threat, due in part to the emergence of drug-resistant bacteria for which we do not have therapies,” said Erin Duffy, R&D Chief of CARB-X. “Polyphor’s project enriches the pool of novel approaches to deliver a therapeutic that can treat infections caused by multidrug-resistant Gram-negative pathogens for which we have few options. It is in the early stages of development, and if successful and approved, it could potentially change the way these life-threatening infections are treated and save lives.”
Share this article
Sign up to receive our newsletter in your inbox.
You may also be interested in
Space Pharmaceuticals establishes presence in Basel
Space Pharmaceuticals AG is strengthening the life sciences cluster in the Basel Area. At its research lab, the cheminformatics company...
Read MoreNextImmune to benefit from Venture Kick financing
The startup accelerator Venture Kick is supporting NextImmune with financing in the amount of 150,000 Swiss francs. The spin-off from...
Read MoreOECD impressed by the canton of Jura’s innovation system
The OECD has examined the innovation systems in place in rural areas of its member states, including the canton of...
Read Moreti&m opens branch in Basel
ti&m now has an office in Basel. With this action, the company specializing in digitization, security and innovation projects is...
Read MoreWhat can artificial intelligence do for health?
Algorithms help diagnose and treat diseases, discover new drugs and personalize prevention. Thus, the potential of artificial intelligence has been...
Read MoreEconomic promotion agency creates 55 new jobs in Jura
The economic promotion agency of the canton of Jura supported a total of 26 companies in founding, establishing a presence...
Read More